Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, Gorevic PD, Litchy WJ, Wiesman JF, Nordh E, Corato M, Lozza A, Cortese A, Robinson-Papp J, Colton T, Rybin DV, Bisbee AB, Ando Y, Ikeda S, Seldin DC, Merlini G, Skinner M, Kelly JW, Dyck PJ.  Diflunisal Trial Consortium.  Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.  JAMA, 310(24):2658-67, 2013.  View in: PubMed

Cowan AJ, Skinner M, Seldin DC, Berk JL, Lichtenstein DR, O’ Hara CJ, Doros G, Sanchorawala V.  Amyloidosis of the gastrointestinal tract: a 13-year single center referral experience. Haematologica, 98(1):141-146, 2013.  View in: PubMed

Leung A, Nah SK, Reid W, Ebata A, Koch CM, Monti S, Genereux JC, Wiseman RL, Wolozin B, Connors LH, Berk JL, Seldin DC, Mostoslavsky G, Kotton DN, Murphy GJ.  Induced pluripotent stem cell modeling of multisystemic, hereditary transthyretin amyloidosis.  Stem Cell Reports, 1(5):451-63, 2013.  View in: PubMed

Sanchorawala V, Patel JM, Sloan JM, Shelton AC, Zeldis JB, Seldin DC.  Melphalan, lenalidomide and dexamethasone for the treatment of AL amyloidosis: results of a phase II trial.  Haematologica, 98 (5):789-792, 2013.  View in: PubMed

Taimur S, Nader C, Lloyd-Travaglini C, Seldin DC, Sanchorawala V.  Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis.  Transpl Infect Dis, 15(2):187-94, 2013.  View in: PubMed

Sarosiek S, Seldin DC, Berk JL, Sanchorawala V.  A solitary mediastinal mass due to localized AL amyloidosis: case report and review of the literature.  Amyloid: J Prot Folding Disorders, 20(2):127-30, 2013.  View in: PubMed

Ruberg FL, Miller EJ.  Nuclear tracers for transthyretin cardiac amyloidosis: time to bone up?  Circ Cardiovasc Imaging, 6(2):162-4, 2013.  View in: PubMed

Sanchorawala V, Shelton AC, Zeldis JB, Seldin DC.  Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide.  Am J Hematol, 88(8):719, 2013.  View in: PubMed

Girnius S, Seldin DC, Cibeira MT, Sanchorawala V.  New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation.  J Clin Oncol, 31(21):2749-50, 2013.  View in: PubMed

Sanchorawala V, Hoering A, Seldin DC, Finn KT, Fennessey SA, Sexton R, Mattar B, Safah HF, Holmberg LA, Dean RM, Orlowski RZ, Barlogie B.  Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.  Bone Marrow Transplant, 48(12):1537-42, 2013.  View in: PubMed

Tanaka K, Essick EE, Doros G, Tanriverdi K, Connors LH, Seldin DC, Sam F.  Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis.  J Am Heart Assoc, 2(2):e005868, 2013.  View in: PubMed

Mishra S, Guan J, Plovie E, Seldin DC, Connors LH, Merlini G, Falk RH, MacRae CA, Liao R.  Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish.  Am J Physiol Heart Circ Physiol, 305(1):H95-103, 2013.  View in: PubMed

Guan J, Mishra S, Shi J, Plovie E, Qiu Y, Cao X, Gianni D, Jiang B, Del Monte F, Connors LH, Seldin DC, Lavatelli F, Rognoni P, Palladini G, Merlini G, Falk RH, Semigran MJ, Dec GW, Macrae CA, Liao R.  Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity.  Basic Res Cardiol, 108(5):378, 2013.  View in: PubMed

Ruberg FL.  T1 mapping in cardiac amyloidosis: can we get there from here?  JACC Cardiovasc Imaging, 6(4):498-500, 2013.  View in: PubMed